Clinical Scorecard: Talking to Patients About Geographic Atrophy
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic atrophy (GA), the most advanced form of dry age-related macular degeneration (AMD), characterized by degeneration of the central retina causing blind spots. |
| Key Mechanisms | Degeneration of central retinal tissue leading to progressive central vision loss; treatments target the complement system to slow progression. |
| Target Population | Patients diagnosed with geographic atrophy, typically older adults with advanced dry AMD. |
| Care Setting | Optometry and retina specialist clinics; initial diagnosis and education by optometrists, treatment administered by retina specialists. |
Key Highlights
- GA causes progressive central vision loss with symptoms including difficulty in low light, distorted vision, and blind spots, but peripheral vision is preserved.
- Two novel intravitreal medications targeting the complement system are approved to slow GA progression but do not reverse or stop the disease.
- Treatment involves ongoing eye injections every 1-2 months, generally well tolerated with transient mild eye irritation.
Guideline-Based Recommendations
Diagnosis
- Use fundus autofluorescence imaging to identify GA lesions and explain the diagnosis to patients with visual aids.
- Recognize early symptoms such as difficulty with nighttime driving, poor illumination vision, and reading fine print.
Management
- Refer patients to retina specialists for evaluation and initiation of complement-inhibiting intravitreal injections.
- Educate patients on lifestyle modifications, vitamin supplementation, and low vision aids as supportive measures.
- Discuss treatment goals clearly: slowing progression to preserve vision longer, not improving or curing GA.
Monitoring & Follow-up
- Regular follow-up with retina specialists to assess disease progression and treatment response.
- Monitor for injection tolerance and manage transient post-injection eye irritation.
Risks
- Inform patients that injections may cause temporary eye irritation but are generally well tolerated.
- Clarify that despite treatment, GA will likely progress over time, and vision loss may continue.
Patient & Prescribing Data
Patients with diagnosed geographic atrophy secondary to dry AMD.
Intravitreal injections targeting the complement system slow GA progression; treatments require long-term, regular administration and do not restore lost vision.
Clinical Best Practices
- Communicate the diagnosis of GA with empathy and clarity to reduce patient anxiety and fear.
- Use visual aids such as fundus autofluorescence images to help patients understand their condition.
- Empower patients with up-to-date information to facilitate informed decision-making and prepare them for specialist consultations.
- Tailor conversations to individual patient scenarios, considering disease status, patient goals, and willingness to pursue treatment.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.